1 차 IGA 신장 신장 상태를 가진 성인의 메자기타 맙 연구
3 단계 다기관, 무작위, 이중 맹검, 위약 통제 시험은 안정적인 배경 요법과 함께 1 차 IGA 신장 병증을 가진 연구 참가자에서 Mezagitamab (TAK-079)의 효능 및 안전성을 평가하기위한 시험.
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo.
Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed by chance in either the mezagitamab or placebo treatment group at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. Participants can be in the study for 2 years (104 weeks). Participants will receive study treatment for about half a year (22 weeks) and then be observed for the remainder of the study (about 1.5 years). During observation, participants will continue to have check-ups about every month.
In the open-label group, a small number of participants who either have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab.
During the study, participants will visit their study clinic several times.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Takeda Contact
- 전화번호: +1-877-825-3327
- 이메일: medinfoUS@takeda.com
연구 장소
-
-
-
Leiden, 네덜란드, 2333 ZA
- 모병
- Leids Universitair Medisch Center
-
연락하다:
- Site Contact
-
수석 연구원:
- Joris Rotmans
-
Nieuwegein, 네덜란드, 3435CM
- 모병
- Sint Antonius ziekenhuis Utrecht/Nieuwegein
-
연락하다:
- Site Contact
-
수석 연구원:
- Gurbey Ocak
-
Nijmegen, 네덜란드, 6525 GA
- 모병
- Radboud Universitair Medisch Centrum
-
연락하다:
- Site Contact
-
수석 연구원:
- Raphael Duivenvoorden
-
Utrecht, 네덜란드, 3584 CX
- 모병
- UMC Utrecht
-
연락하다:
- Site Contact
-
수석 연구원:
- Sabine Meijvis
-
-
North Holland
-
Amsterdam, North Holland, 네덜란드, 1105 AZ
- 모병
- Amsterdam UMC - Locatie AMC (Academisch Medisch Centrum)
-
연락하다:
- Site Contact
-
수석 연구원:
- Marc Hilhorst
-
-
-
-
-
Bergen, 노르웨이, 5021
- 모병
- Haukeland Universitetssjukehus
-
연락하다:
- Site Contact
-
수석 연구원:
- Thomas Knoop
-
Grålum, 노르웨이, 1714
- 모병
- Sykehuset Ostfold
-
연락하다:
- Site Contact
-
수석 연구원:
- Dumitrescu Ioana-Elena
-
Stavanger, 노르웨이
- 모병
- Stavanger Universitetssjukehus - Helse Stavanger HF
-
연락하다:
- Site Contact
-
수석 연구원:
- Goransson Lasse
-
Trondheim, 노르웨이, 7030
- 모병
- Universitetssykehuset I Trondheim - St. Olavs Hospital - Nevroklinikken
-
연락하다:
- Site Contact
-
수석 연구원:
- Yngvar Haaskjold
-
-
Akershus
-
Lorenskog, Akershus, 노르웨이, 1478
- 모병
- Akershus University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Bartlomiej Witczak
-
-
Vestfold
-
Tønsberg, Vestfold, 노르웨이
- 모병
- Sykehuset I Vestfold
-
연락하다:
- Site Contact
-
수석 연구원:
- Kjellevold Stig Arne
-
-
-
-
-
Kaohsiung City, 대만, 807
- 모병
- Kaohsiung Medical University - Chung-Ho Memorial Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Yi Wen Chiu
-
New Taipei City, 대만
- 모병
- Taipei Medical University Shuang Ho Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Mai-Szu Wu
-
Taichung, 대만, 40705
- 모병
- Taichung Veterans General Hospital
-
수석 연구원:
- Ming-Ju Wu
-
연락하다:
- Site Contact
-
Taichung, 대만
- 모병
- China Medical University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Ping-Chin Lai
-
Zhongzheng, 대만, 100
- 모병
- National Taiwan University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Jenq-Wen Huang
-
-
-
-
-
Seoul, 대한민국, 3722
- 모병
- Severance Hospital, Yonsei University Health System
-
수석 연구원:
- Seung Hyeok Han
-
연락하다:
- Site Contact
-
Seoul, 대한민국, 3080
- 모병
- Seoul National University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Dong Ki Kim
-
Seoul, 대한민국, 7061
- 모병
- Seoul National University Boramae Medical Center
-
연락하다:
- Site Contact
-
수석 연구원:
- Jung Pyo Lee
-
-
Gyeonggi-do
-
Yongin-si, Gyeonggi-do, 대한민국, 16995
- 모병
- Yongin Severance Hospital, Yonsei University Health System
-
연락하다:
- Site Contact
-
수석 연구원:
- Young Su Joo
-
-
Gyeonggido
-
Suwon, Gyeonggido, 대한민국, 16499
- 모병
- Ajou University Hospital-Primary Research Location
-
연락하다:
- Site Contact
-
수석 연구원:
- Inwhee Park
-
-
Seongnam
-
Seongnam-si, Seongnam, 대한민국, 13620
- 모병
- Seoul National University Bundang Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Ho-Jun Chin
-
-
-
-
-
Mainz, 독일, 55131
- 모병
- Universitaetsmedizin der Johannes - Gutenberg Universitaet Mainz
-
연락하다:
- Site Contact
-
수석 연구원:
- Julia Weinmann-Manke
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, 독일, 52074
- 모병
- Uniklinik RWTH Aachen
-
연락하다:
- Site Contact
-
수석 연구원:
- Claudia Seikrit
-
-
Thuringia
-
Jena, Thuringia, 독일, 7747
- 모병
- Universitaetsklinikum Jena
-
연락하다:
- Site Contact
-
수석 연구원:
- Martin Busch
-
-
-
-
-
Kuala Lumpur, 말레이시아, 50603
- 모병
- Universiti Malaya Medical Centre (UMMC)
-
연락하다:
- Site Contact
-
수석 연구원:
- Soo Kun Lim
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, 말레이시아, 56000
- 모병
- Universiti Kebangsaan Malaysia (UKM) - Medical Centre (Pusat Perubatan) (Hospital Canselor Tuanku Muhriz (HCTM))
-
연락하다:
- Site Contact
-
수석 연구원:
- Lydia Kamaruzaman
-
-
Pahang
-
Kuantan, Pahang, 말레이시아, 25100
- 모병
- Hospital Tengku Ampuan Afzan
-
연락하다:
- Site Contact
-
수석 연구원:
- Fariz Safhan Mohamad Nor
-
-
Perak
-
Taiping, Perak, 말레이시아, 34000
- 모병
- Hospital Taiping
-
연락하다:
- Site Contact
-
수석 연구원:
- Kok Seng Teng
-
-
Selangor
-
Kajang, Selangor, 말레이시아, 43000
- 모병
- Hospital Sultan Idris Shah Serdang (Hospital Serdang)
-
연락하다:
- Site Contact
-
수석 연구원:
- Li Lian Tay
-
Subang Jaya, Selangor, 말레이시아, 47500
- 모병
- Sunway Medical Centre (SMC)
-
연락하다:
- Site Contact
-
수석 연구원:
- Rosnawati Yahya
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233-2110
- 모병
- UAB Nephrology Research Clinic at Paula Building
-
수석 연구원:
- Dana Rizk
-
연락하다:
- Site Contact
-
Montgomery, Alabama, 미국, 36117
- 모병
- DCR Montgomery
-
수석 연구원:
- Vinayak Ramanath
-
연락하다:
- Site Contact
-
-
Arizona
-
Surprise, Arizona, 미국, 85374
- 모병
- Panoramic Health - Southwest Kidney Institute, PLC
-
연락하다:
- Site Contact
-
수석 연구원:
- Minesh Rajpal
-
-
California
-
Fremont, California, 미국, 94538
- 모병
- Panoramic Health - West Coast Kidney Institute (Fremont)
-
연락하다:
- Site Contact
-
수석 연구원:
- Varun Chawla
-
Los Angeles, California, 미국, 90022
- 모병
- Academic Medical Research Institute
-
연락하다:
- Site Contact
-
수석 연구원:
- Mohammed El-Shahwy
-
Los Angeles, California, 미국, 90095
- 모병
- UCLA University of California Los Angeles
-
연락하다:
- Site Contact
-
수석 연구원:
- Anjay Rastogi
-
Orange, California, 미국, 92868-3201
- 모병
- University of California Irvine
-
연락하다:
- Site Contact
-
수석 연구원:
- Ramy Hanna
-
San Francisco, California, 미국, 94118
- 모병
- Kaiser Permanente San Francisco Medical Center
-
연락하다:
- Site Contact
-
수석 연구원:
- Ali Poyan-Mehr
-
-
Florida
-
Jacksonville, Florida, 미국, 32250
- 모병
- Panoramic Health - Florida Kidney Physicians, LLC (Jacksonville)
-
연락하다:
- Site Contact
-
수석 연구원:
- Prasanth Krish
-
Lauderdale Lakes, Florida, 미국, 33313-1607
- 모병
- South Florida Research Institute
-
연락하다:
- Site Contact
-
수석 연구원:
- Edouard Martin
-
Melbourne, Florida, 미국, 32901
- 모병
- Panoramic Health - Florida Kidney Physicians, LLC (Melbourne)
-
연락하다:
- Site Contact
-
수석 연구원:
- Claus Peter Spies
-
Miami, Florida, 미국, 33127
- 모병
- Bioresearch Partners
-
연락하다:
- Site Contact
-
수석 연구원:
- Jose Miguel Cardona-Guzman
-
Miami, Florida, 미국, 33176
- 모병
- Total Health and Research Center (THRC)
-
연락하다:
- Site Contact
-
수석 연구원:
- Jeffrey Maldonado
-
Orlando, Florida, 미국, 32806
- 모병
- CTR Oakwater, LLC
-
연락하다:
- Site Contact
-
수석 연구원:
- Arvind Madan
-
Pembroke Pines, Florida, 미국, 33029
- 모병
- Bioresearch Partners
-
연락하다:
- Site Contact
-
수석 연구원:
- Max Benjamin
-
Riverview, Florida, 미국, 33578
- 모병
- Panoramic Health - Florida Kidney Physicians, LLC (Tampa)
-
연락하다:
- Site Contact
-
수석 연구원:
- Amit Augustine Johnsingh
-
Sanford, Florida, 미국, 32771
- 모병
- Infigo Clinical Research LLC
-
연락하다:
- Site Contact
-
수석 연구원:
- Sayed Husain
-
-
Georgia
-
Columbus, Georgia, 미국, 31904
- 모병
- DCR Columbus
-
연락하다:
- Site Contact
-
수석 연구원:
- Tamorie Smith
-
East Point, Georgia, 미국, 30344
- 모병
- Panoramic Health - Southeast Kidney Associates
-
연락하다:
- Site Contact
-
수석 연구원:
- Charmaine Ifeoma Emelife
-
-
Idaho
-
Boise, Idaho, 미국, 83706
- 모병
- CARE Institute - Boise Kidney
-
연락하다:
- Site Contact
-
수석 연구원:
- Arnold Silva
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Northwestern University
-
연락하다:
- Site Contact
-
수석 연구원:
- Yonatan Peleg
-
Rockford, Illinois, 미국, 61107
- 모병
- Panoramic Health - RNA of Rockford, LLC dba Rockford Nephrology Associates
-
연락하다:
- Site Contact
-
수석 연구원:
- Syed Mustafa Ahmed
-
-
Louisiana
-
Shreveport, Louisiana, 미국, 71101
- 모병
- Northwest Louisiana Nephrology
-
연락하다:
- Site Contact
-
수석 연구원:
- Marwan Kaskas
-
-
Michigan
-
Lansing, Michigan, 미국, 48911
- 모병
- Ingham Nephrology & Hypertension, P.C.
-
연락하다:
- Site Contact
-
수석 연구원:
- Brian Cousino
-
Pontiac, Michigan, 미국, 48341
- 모병
- Elixia MKC
-
연락하다:
- Site Contact
-
수석 연구원:
- Fahd Al-Saghir
-
Saint Joseph, Michigan, 미국, 49085
- 모병
- Panoramic Health - Lake Michigan Nephrology, PLC
-
연락하다:
- Site Contact
-
수석 연구원:
- Oliver Chambers Songlingco
-
-
Minnesota
-
Edina, Minnesota, 미국, 55435
- 모병
- DCR Edina
-
연락하다:
- Site Contact
-
수석 연구원:
- Shannon Doyle
-
-
Missouri
-
City of Saint Peters, Missouri, 미국, 63376
- 모병
- Elixia MNA
-
연락하다:
- Site Contact
-
수석 연구원:
- Gary Singer
-
Kansas City, Missouri, 미국, 64111
- 모병
- Clinical Research Consultants a JCCT Company
-
연락하다:
- Site Contact
-
수석 연구원:
- Ahmed Awad
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87109
- 모병
- Renal Medicine Associates - Frenova F1
-
연락하다:
- Site Contact
-
수석 연구원:
- Jayant Kumar
-
-
North Carolina
-
Winston-Salem, North Carolina, 미국, 27103
- 모병
- Brookview Hills Research Associates, LLC
-
수석 연구원:
- Nicholas McLean
-
연락하다:
- Site Contact
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45212
- 모병
- Panoramic Health - Kidney and Hypertension Center
-
연락하다:
- Site Contact
-
수석 연구원:
- James Davis
-
-
Pennsylvania
-
Media, Pennsylvania, 미국, 19063
- 모병
- Panoramic Health - Clinical Renal Associates, Ltd.
-
연락하다:
- Site Contact
-
수석 연구원:
- Nathan Okechukwu
-
Philadelphia, Pennsylvania, 미국, 19107
- 모병
- Thomas Jefferson University
-
연락하다:
- Site Contact
-
수석 연구원:
- Charlene Deng
-
-
Rhode Island
-
East Providence, Rhode Island, 미국, 02914
- 모병
- Panoramic Health - Nephrology Associates, Inc.
-
연락하다:
- Site Contact
-
수석 연구원:
- Larissa Kruger Gomes
-
-
Texas
-
Dallas, Texas, 미국, 75230
- 모병
- Dallas Renal Group
-
수석 연구원:
- Irfan Agha
-
연락하다:
- Site Contact
-
El Paso, Texas, 미국, 79902
- 모병
- DCR - El Paso
-
연락하다:
- Site Contact
-
수석 연구원:
- Simon Rodriguez
-
Houston, Texas, 미국, 77054
- 모병
- Provecta Research Network
-
연락하다:
- Site Contact
-
수석 연구원:
- Sreedhar Mandayam
-
Houston, Texas, 미국, 77030
- 모병
- Houston Methodist Research Institute - Department of Medicine
-
연락하다:
- Site Contact
-
수석 연구원:
- Peter Nguyen
-
Katy, Texas, 미국, 77450
- 모병
- Nephrology Associates of Houston PLLC
-
연락하다:
- Site Contact
-
수석 연구원:
- Syed Hussain
-
San Antonio, Texas, 미국, 78215
- 모병
- Sun Research Institute
-
연락하다:
- Site Contact
-
수석 연구원:
- Reyes Leonel
-
San Antonio, Texas, 미국, 78251
- 모병
- DCR San Antonio
-
연락하다:
- Site Contact
-
수석 연구원:
- Tahira Alves
-
-
Utah
-
Salt Lake City, Utah, 미국, 84115
- 모병
- Utah Kidney Research Institute
-
연락하다:
- Site Contact
-
수석 연구원:
- Sanjiv Anand
-
-
Virginia
-
Arlington, Virginia, 미국, 22205
- 모병
- Panoramic Health - Virginia Nephrology Group
-
연락하다:
- Site Contact
-
수석 연구원:
- Renuka Sothinathan
-
-
West Virginia
-
Morgantown, West Virginia, 미국, 26506
- 모병
- West Virginia University
-
연락하다:
- Site Contact
-
수석 연구원:
- Bethany Pellegrino
-
-
-
-
-
Linköping, 스웨덴
- 모병
- Renal Medicine Linkoping University/ Linkoping University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Annette Bruchfeld
-
-
-
-
-
Zurich, 스위스, 8091
- 모병
- University Hospital Zurich
-
연락하다:
- Site Contact
-
수석 연구원:
- Britta George
-
-
-
-
-
Barcelona, 스페인, 8035
- 모병
- Hospital Universitari Vall d'Hebron
-
연락하다:
- Site Contact
-
수석 연구원:
- Irene Agraz Pamplona
-
Barcelona, 스페인, 8003
- 모병
- Hospital del Mar
-
연락하다:
- Site Contact
-
수석 연구원:
- Eva Rodriguez Garcia
-
Madrid, 스페인, 28027
- 모병
- Universidad de Navarra - Clinica Universidad de Navarra
-
연락하다:
- Site Contact
-
수석 연구원:
- Jose Maria Mora Gutierrez
-
Madrid, 스페인, 28040
- 모병
- Fundacion Jimenez Diaz
-
연락하다:
- Site Contact
-
수석 연구원:
- Roberto Scarpioni
-
Seville, 스페인, 41013
- 모병
- Hospital Universitario Virgen del Rocio - PPDS
-
연락하다:
- Site Contact
-
수석 연구원:
- Manuel Lopez Mendoza
-
-
Barcelona
-
Badalona, Barcelona, 스페인, 8915
- 모병
- Hospital Universitari Germans Trias i Pujol
-
연락하다:
- Site Contact
-
수석 연구원:
- Iara Karlla Da Silva Santos
-
-
Bizkaia
-
Barakaldo, Bizkaia, 스페인, 48903
- 모병
- Hospital Universitario de Cruces
-
연락하다:
- Site Contact
-
수석 연구원:
- Laura Bueno Lopez
-
-
Navarre
-
Pamplona, Navarre, 스페인, 31008
- 모병
- Universidad de Navarra - Clinica Universidad de Navarra
-
연락하다:
- Site Contact
-
수석 연구원:
- Jose Maria Mora Gutierrez
-
-
-
-
-
Ljubljana, 슬로베니아, 1000
- 모병
- University Medical Centre Ljubljana
-
연락하다:
- Site Contact
-
수석 연구원:
- Andreja Ales Rigler
-
Maribor, 슬로베니아
- 모병
- University Clinical Centre Maribor
-
연락하다:
- Site Contact
-
수석 연구원:
- Sebastjan Bevc
-
-
-
-
-
Singapore, 싱가포르
- 모병
- National University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Boon Wee Teo
-
Singapore, 싱가포르, 169608
- 모병
- Singapore General Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Jason Choo
-
Singapore, 싱가포르, 308433
- 모병
- Tan Tock Seng Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- See Cheng Yeo
-
-
-
-
-
Ciudad Autonoma Buenos Aires, 아르헨티나, 1280
- 모병
- Hospital Britanico de Buenos Aires
-
연락하다:
- Site Contact
-
수석 연구원:
- Hernan Trimarchi Jurado
-
Córdoba, 아르헨티나, X5016
- 모병
- Clinica Privada Velez Sarsfield
-
연락하다:
- Site Contact
-
수석 연구원:
- Rafael Alberto Maldonado
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, 아르헨티나, C1425AGC
- 모병
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
-
연락하다:
- Site Contact
-
수석 연구원:
- Alejandra Smuclir Quevedo
-
-
La Plata
-
Buenos Aires, La Plata, 아르헨티나, 1902
- 모병
- Framingham Centro Medico
-
연락하다:
- Site Contact
-
수석 연구원:
- Martin Mamberti
-
-
-
-
-
Canterbury, 영국, CT1 3PA
- 모병
- Kent & Canterbury Hospital, Canterbury
-
연락하다:
- Site Contact
-
수석 연구원:
- Tharindra Somasinghe
-
Hull, 영국
- 모병
- Hull University Teaching Hospitals NHS Trust
-
연락하다:
- Site Contact
-
수석 연구원:
- Sunil Bhandari
-
Leicester, 영국
- 모병
- Leicester General Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Chee Kay Cheung
-
London, 영국, WC2R 2LS
- 모병
- King's College Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Sapna Shah
-
London, 영국, SW17 0QT
- 모병
- St George's University Hospitals NHS Foundation Trust
-
연락하다:
- Site Contact
-
수석 연구원:
- Richard Hull
-
Nottingham, 영국
- 모병
- Nottingham University Hospitals NHS Trust - City Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Matthew Hall
-
Preston, 영국, PR29HT
- 모병
- Lancashire Teaching Hospital NHS Foundation Trust
-
연락하다:
- Site Contact
-
수석 연구원:
- Arvind Ponnusamy
-
Sheffield, 영국
- 모병
- Northern General Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Arif Khwaja
-
-
Greater London
-
London, Greater London, 영국, SE1 9RT
- 모병
- Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Dimitrios-Anestis Moutzouris
-
-
United Kingdom of Great Britain and Northern Ireland
-
Birmingham, United Kingdom of Great Britain and Northern Ireland, 영국
- 모병
- Birmingham Heartlands Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Bamidele Tokunbo Ajayi
-
-
-
-
-
Linz, 오스트리아, 4040
- 모병
- Johannes Kepler Universitat Linz, Universitatsklinik fur Innere 2
-
연락하다:
- Site Contact
-
수석 연구원:
- Alexander Moschen
-
Vienna, 오스트리아, 1090
- 모병
- Medizinische Universitat Wien (Medical University of Vienna - Austria)
-
수석 연구원:
- Rainer Oberbauer
-
연락하다:
- Site Contact
-
-
-
-
-
Bologna, 이탈리아, 40138
- 모병
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
-
연락하다:
- Site Contact
-
수석 연구원:
- Gaetano La Manna
-
Brescia, 이탈리아, 25124
- 모병
- ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
-
연락하다:
- Site Contact
-
수석 연구원:
- Federica Mescia
-
Genoa, 이탈리아, 16132
- 모병
- IRCCS Ospedale Policlinico San Martino
-
연락하다:
- Site Contact
-
수석 연구원:
- Francesca Viazzi
-
Messina, 이탈리아, 98122
- 모병
- Az Ospedaliera Universitaria Policlinico G Martino
-
연락하다:
- Site Contact
-
수석 연구원:
- Domenico Santoro
-
Milan, 이탈리아, 20100
- 모병
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
연락하다:
- Site Contact
-
수석 연구원:
- Giuseppe Castellano
-
Pavia, 이탈리아, 27100
- 모병
- Istituto Maugeri IRCCS Pavia
-
수석 연구원:
- Ciro Esposito
-
연락하다:
- Site Contact
-
Piacenza, 이탈리아, 29121
- 모병
- Azienda Unita Sanitaria Locale Piacenza (AUSL) Ospedale "Guglielmo da Saliceto
-
연락하다:
- Site Contact
-
수석 연구원:
- Roberto Scarpioni
-
Torino, 이탈리아, 10126
- 모병
- AOU Citta della Salute e della Scienza di Torino
-
연락하다:
- Site Contact
-
수석 연구원:
- Luigi Biancone
-
-
-
-
Aichi-ken
-
Kasugai-Shi, Aichi-ken, 일본, 486-8510
- 모병
- Kasugai Municipal Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Yosuke Saka
-
Nagoya, Aichi-ken, 일본, 466-8650
- 모병
- Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Shoji Saito
-
Toyoake-shi, Aichi-ken, 일본, 470-1192
- 모병
- Fujita Health University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Naotake Tsuboi
-
-
Chiba
-
Chiba, Chiba, 일본, 260-8712
- 모병
- National Hospital Organization Chiba Medical Center Chibahigashi National Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Takehiko Kawaguchi
-
-
Fukuoka
-
Fukuoka, Fukuoka, 일본, 812-8582
- 모병
- Kyushu University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Toshiaki Nakano
-
-
Fukushima
-
Fukushima, Fukushima, 일본, 960-1295
- 모병
- Fukushima Medical University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Kazama Junichiro
-
-
Hiroshima
-
Hiroshima, Hiroshima, 일본, 734-8551
- 모병
- Hiroshima University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Takao Masaki
-
-
Hokkaido
-
Sapporo, Hokkaido, 일본, 060-8648
- 모병
- Hokkaido University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Daigo Nakazawa
-
-
Kanagawa
-
Kamakura-shi, Kanagawa, 일본, 247-8533
- 모병
- Shonan Kamakura General Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Hidaka Sumi
-
Kawasaki-shi, Kanagawa, 일본, 213-8587
- 모병
- Toranomon Hospital Kajigaya
-
연락하다:
- Site Contact
-
수석 연구원:
- Naoki Sawa
-
Yokohama, Kanagawa, 일본, 236-0004
- 모병
- Yokohama City University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Kouichi Tamura
-
-
Miyagi
-
Sendai, Miyagi, 일본, 981-3281
- 모병
- Japan Community Health care Organization Sendai Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Santoru Sanada
-
-
Nara
-
Kashihara-shi, Nara, 일본, 634-8522
- 모병
- Nara Medical University Hospital
-
수석 연구원:
- Kazuhiko Tsuruya
-
연락하다:
- Site Contact
-
Nara, Nara, 일본, 630-8581
- 모병
- Nara Prefecture General Medical Center
-
연락하다:
- Site Contact
-
수석 연구원:
- Hideo Tsushima
-
-
Oita Prefecture
-
Yufu-shi, Oita Prefecture, 일본, 879-5593
- 모병
- Oita University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Fukuda Akihiro
-
-
Osaka
-
Osaka, Osaka, 일본, 530-8480
- 모병
- Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofuka
-
연락하다:
- Site Contact
-
수석 연구원:
- Takeshi Matsubara
-
-
Saitama
-
Koshigaya-shi, Saitama, 일본, 343-8555
- 모병
- Dokkyo Medical University Saitama Medical Center
-
수석 연구원:
- Tetsuro Takeda
-
연락하다:
- Site Contact
-
-
Tokyo
-
Bunkyo-ku, Tokyo, 일본, 113-8431
- 모병
- Juntendo University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Yusuke Suzuki
-
Shinjuku-Ku, Tokyo, 일본, 160-0023
- 모병
- Tokyo Medical University Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Takahito Moriyama
-
-
Yamanashi
-
Chuo-shi, Yamanashi, 일본, 409-3898
- 모병
- University of Yamanashi Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Ayumu Nakashima
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100034
- 모병
- Peking University First Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Jicheng Lv
-
Changping, Beijing Municipality, 중국, 102218
- 모병
- Beijing Tsinghua Changgung Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Yuehong Li
-
-
Fujian
-
Xiamen, Fujian, 중국, 361004
- 모병
- Zhongshan Hospital Xiamen University
-
연락하다:
- Site Contact
-
수석 연구원:
- Bo Xu
-
-
Guangdong
-
Guangdong, Guangdong, 중국, Guangdong
- 모병
- The First Affiliated Hospital of Sun Yat-sen University
-
연락하다:
- Site Contact
-
수석 연구원:
- Wei Chen
-
Guangzhou, Guangdong, 중국, 510080
- 모병
- Guangdong General Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Zhiming Ye
-
Shenzhen, Guangdong, 중국, 518000
- 모병
- Peking University Shenzhen Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Zu-Ying Xiong
-
-
Hunan
-
Changsha, Hunan, 중국, 410013
- 모병
- The Third Xiangya Hospital of Central South University Yuelu District
-
수석 연구원:
- Hao Zhang
-
연락하다:
- Site Contact
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, 중국, 14010
- 모병
- The First Affiliated Hospital of Baotou Medical College
-
연락하다:
- Site Contact
-
수석 연구원:
- Zengyan Li
-
-
Jiangsu
-
Nanjing, Jiangsu, 중국, 210009
- 모병
- Zhongda Hospital Southeast University
-
연락하다:
- Site Contact
-
수석 연구원:
- Liu Bicheng
-
Nantong, Jiangsu, 중국, 226001
- 모병
- Affiliated Hospital of Nantong University
-
연락하다:
- Site Contact
-
수석 연구원:
- Xinzhong Huang
-
Wuxi, Jiangsu, 중국, 214023
- 모병
- Wuxi People's Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Liang Wang
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330006
- 모병
- The First Affiliated Hospital of Nanchang University
-
연락하다:
- Site Contact
-
수석 연구원:
- Yan Yan
-
-
Shandong
-
Jinan, Shandong, 중국, 250012
- 모병
- Shandong University - Qilu Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Xiang-Dong Yang
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200000
- 모병
- Shanghai Jiao Tong University School of Medicine (SJTUSM) - Renji Hospital - Eastern Branch
-
연락하다:
- Site Contact
-
수석 연구원:
- Leyi Gu
-
Shanghai, Shanghai Municipality, 중국, 200025
- 모병
- Ruijin Hospital of Shanghai Jiaotong University School of Medicine
-
연락하다:
- Site Contact
-
수석 연구원:
- Jingyuan Xie
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610000
- 모병
- West China Hospital Sichuan University
-
수석 연구원:
- Ping Fu
-
연락하다:
- Site Contact
-
Chengdu, Sichuan, 중국, 610072
- 모병
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Guisen Li
-
Yibin, Sichuan, 중국, 644099
- 모병
- The Second People's Hospital of Yibin
-
연락하다:
- Site Contact
-
수석 연구원:
- Deqiong Xie
-
-
Xiangzhou District, Guangdong Province
-
Zhuhai, Xiangzhou District, Guangdong Province, 중국, 519000
- 모병
- Fifth Affiliated Hospital Sun Yat-Sen University
-
연락하다:
- Site Contact
-
수석 연구원:
- Cheng Wang
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국
- 모병
- The Second Affiliated Hospital, Zhejiang University, School of Medicine
-
연락하다:
- Site Contact
-
수석 연구원:
- Kunling Ma
-
Ningbo, Zhejiang, 중국, 315010
- 모병
- The First Affiliated Hospital of Ningbo University
-
연락하다:
- Site Contact
-
수석 연구원:
- Xueyan Bian
-
-
-
-
-
Olomouc, 체코, 779 00
- 모병
- Fakultni nemocnice Olomouc
-
연락하다:
- Site Contact
-
수석 연구원:
- Karel Krejci
-
Prague, 체코
- 모병
- First Faculty of Medicine Charles University
-
연락하다:
- Site Contact
-
수석 연구원:
- Vladimir Tesar
-
-
Moravskoslezsk Kraj
-
Nový Jičín, Moravskoslezsk Kraj, 체코, 741 01
- 모병
- Nemocnice AGEL Novy Jicin a.s
-
연락하다:
- Site Contact
-
수석 연구원:
- Vaclava Honova
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2R 0X7
- 모병
- Sheldon M. Chumir Health Centre
-
연락하다:
- Site Contact
-
수석 연구원:
- Louis Girard
-
-
Ontario
-
London, Ontario, 캐나다, N6A5A5
- 모병
- London Health Sciences Centre
-
연락하다:
- Site Contact
-
수석 연구원:
- Matthew Weir
-
Toronto, Ontario, 캐나다, M4G 3E8
- 모병
- Sunnybrook Health Sciences Centre
-
연락하다:
- Site Contact
-
수석 연구원:
- Michelle Hladunewich
-
-
-
-
-
Kocaeli, 터키 (Türkiye)
- 모병
- Kocaeli Universitesi Tip Fakultesi Arastirma ve Uygulama Hastanesi
-
연락하다:
- Site Contact
-
수석 연구원:
- Necmi Eren
-
-
Battalgazi
-
Malatya, Battalgazi, 터키 (Türkiye), 44280
- 모병
- Turgut Ozal Medical Center
-
연락하다:
- Site Contact
-
수석 연구원:
- Ozkan Ulutas
-
-
Gaziantep
-
Şahinbey, Gaziantep, 터키 (Türkiye), 27310
- 모병
- Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi
-
연락하다:
- Site Contact
-
수석 연구원:
- Fatih Mehmet Erdur
-
-
Istanbul
-
Fatih, Istanbul, 터키 (Türkiye), 34098
- 모병
- Istanbul Universitesi Cerrahpasa Tip Fakultesi
-
연락하다:
- Site Contact
-
수석 연구원:
- Nurhan Seyahi
-
-
Melikgazi
-
Kayseri, Melikgazi, 터키 (Türkiye), 38039
- 모병
- Erciyes University
-
연락하다:
- Site Contact
-
수석 연구원:
- Bulent Tokgoz
-
-
Onikisubat
-
Kahramanmaraş, Onikisubat, 터키 (Türkiye), 46040
- 모병
- Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Avsar Mah
-
연락하다:
- Site Contact
-
수석 연구원:
- Orcum Altunoren
-
-
Selcuklu
-
Konya, Selcuklu, 터키 (Türkiye), 42280
- 모병
- Necmettin Erbakan University
-
연락하다:
- Site Contact
-
수석 연구원:
- Kultigin Turkmen
-
-
-
-
-
Gmina Świecie, 폴란드, 86-100
- 모병
- Nowy Szpital Sp Zo.o
-
연락하다:
- Site Contact
-
수석 연구원:
- Andrzej Brymora
-
Krakow, 폴란드, 31-559
- 모병
- SCM Sp. z o.o.
-
연락하다:
- Site Contact
-
수석 연구원:
- Dariusz Aksamit
-
Lodz, 폴란드
- 모병
- Indywidualna Specjalistyczna Praktyka Lekarska
-
수석 연구원:
- Michal Nowicki
-
연락하다:
- Site Contact
-
Wroclaw, 폴란드, 50-981
- 모병
- 4th Military Clinical hospital /Polyclinic SP ZOZ
-
연락하다:
- Site Contact
-
수석 연구원:
- Magdalena Krajewska
-
-
-
-
-
Bordeaux, 프랑스, 33076
- 모병
- CHU Bordeaux, CHU Pellegrin
-
연락하다:
- Site Contact
-
수석 연구원:
- Claire Rigothier
-
Limoges, 프랑스, 87042
- 모병
- CHU Limoges Service de Nephrology
-
연락하다:
- Site Contact
-
수석 연구원:
- Fatouma Toure
-
Montpellier, 프랑스, 34090
- 모병
- Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Lapeyronie
-
연락하다:
- Site Contact
-
수석 연구원:
- Moglie Le Quintrec
-
Nantes, 프랑스, 44093
- 모병
- CHU de Nantes
-
연락하다:
- Site Contact
-
수석 연구원:
- Simon Ville
-
Paris, 프랑스, 75020
- 모병
- Hospital Tenon
-
연락하다:
- Site Contact
-
수석 연구원:
- Khalil Karoui
-
-
Paris
-
Créteil, Paris, 프랑스, 94000
- 모병
- Hospital Henri Mondor
-
연락하다:
- Site Contact
-
수석 연구원:
- Vincent Audard
-
-
-
-
-
Budapest, 헝가리, 1083
- 모병
- Semmelweis Egyetem - Belgyogyaszati es Onkologiai Klinika (I.sz. Belgyogyaszati Klinika)
-
연락하다:
- Site Contact
-
수석 연구원:
- Akos Petho
-
-
-
-
New South Wales
-
Liverpool, New South Wales, 호주
- 모병
- South Western Sydney Local Health District - University of New South Wales - Liverpool Hospital
-
연락하다:
- Site Contact
-
수석 연구원:
- Beata Zahorowska
-
-
Queensland
-
Milton, Queensland, 호주
- 모병
- Core Research Group
-
연락하다:
- Site Contact
-
수석 연구원:
- David Colquhoun
-
-
Victoria
-
Box Hill, Victoria, 호주, 3128
- 모병
- Eastern Health
-
수석 연구원:
- Darren Lee
-
연락하다:
- Site Contact
-
Clayton, Victoria, 호주
- 모병
- Monash Heath - Monash University - Monash Medical Centre
-
연락하다:
- Site Contact
-
수석 연구원:
- Jessica Ryan
-
St Albans, Victoria, 호주, 3021
- 모병
- Western Health Sunshine Hospital
-
수석 연구원:
- Eugenia Pedagogos
-
연락하다:
- Site Contact
-
-
-
-
Hong Kong Island
-
Hong Kong, Hong Kong Island, 홍콩
- 모병
- The University of Hong Kong - Department of Medicine
-
수석 연구원:
- Sydney Chi Wai Tang
-
연락하다:
- Site Contact
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
- Inclusion Criteria:
To be eligible to participate in this trial, participants must meet all the following criteria:
-
Either UPCR greater than or equal to (≥) 0.8 gram per gram (g/g) or urine protein excretion (UPE) ≥1 grams per day (g/day), calculated from at least one 24-hour urine collection during the screening period (or pre-screening, if applicable) (only applicable for the main trial).
-
eGFR greater than (>)30 milliliters per minute per 1.73 meter square (mL/min/1.73m^2) at screening based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (only applicable for the main trial).
-
No prior exposure to anti- cluster of differentiation 38 (CD38) therapy period (except for open-label cohort participants meeting Inclusion Criterion No. 10.a).
-
The participant is aged ≥ 18 years or the local legal age as applicable.
-
The participant (and the participant's legally acceptable representative, as applicable per local regulations or determination) has provided informed consent (that is, in writing, documented via a signed and dated informed consent form [ICF]) and any required privacy authorization before the initiation of any clinical trial procedures.
-
Diagnosis of primary immunoglobulin A nephropathy (IgAN) supported by a renal biopsy report that is dated more recently than 10 years before the signing of the informed consent for the clinical trial. The redacted report must be made available for review. A renal biopsy must be performed during screening for participants without a biopsy report within 10 years.
-
Participants must be on stable renin-angiotensin-aldosterone system (RAAS) inhibitor therapy with an angiotensin-converting enzyme inhibitor (ACE-I) and/or angiotensin receptor blocker (ARB) or endothelin receptor antagonist (ERA) or mineralocorticoid receptor antagonist (MRA) agent for at least 12 weeks before signing the ICF with dosing at the maximally tolerated or labeled dose as determined by the investigator, with the intent to continue stable dosing during the clinical trial. Those intolerant of RAAS inhibitor therapy are potentially eligible after consultation with the medical monitor. Intolerance is defined as a documented side effect causing discontinuation of the therapy.
-
Resting blood pressure less than or equal to (≤)150 millimeters of mercury (mmHg) systolic and ≤100 mmHg diastolic.
-
Female participants of childbearing potential who are not pregnant during screening (confirmed by negative serum human chorionic gonadotropin [hCG]) and on Visit 1 before first dose of trial intervention (confirmed by negative urine pregnancy test).
-
Any one of the following (only applicable for participants in the open-label cohort):
-
Participants in Trial TAK-079-1006 who completed the Week 96 visit or the retreatment period with either UPCR >0.5 g/g or UPE >0.5 g/d calculated from a 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR >30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.
-
UPCR <0.8 g/g and UPE ≥0.75 and <1.0 g/day, by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR > 30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.
-
UPCR ≥ 0.8 g/g or UPE ≥ 1.0 g/d by 24-hour urine collection during the screening period (or pre-screening, if applicable) and eGFR ≥25 and ≤30 mL/min/1.73m^2 at screening based on the CKD-EPI formula.
- Exclusion Criteria:
-
A participant who meets any of the following criteria will be excluded from participation in this trial:
-
Kidney biopsy exhibiting significant concomitant renal disease other than IgAN (for example, diabetic nephropathy, lupus nephritis, minimal change disease).
-
Secondary IgAN (such as with significant liver disease, inflammatory bowel disease, and seronegative spondyloarthropathies), and immunoglobulin A (IgA) vasculitis.
-
Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months before the signing of the ICF).
-
Diagnosis of nephrotic syndrome defined as 24-hour proteinuria >3.5 g/day and hypoalbuminemia (<3.0 grams per deciliter [g/dL]) with or without peripheral edema.
-
Renal or other organ transplantation prior to or expected during the clinical trial.
-
Treatment with oral immunosuppressive agents (including cyclophosphamide, mycophenolate mofetil, cyclosporine, azathioprine, calcineurin inhibitors) or biologic therapy for immunomodulation (including immunomodulatory monoclonal or polyclonal antibodies) within 6 months (both B-cell and non-B-cell directed agents) before signing of the ICF.
-
If the participant has received anti-CD20 treatment, the participant is excluded if either of the following apply:
- The last dose was received within 6 months before the signing of the ICF.
- The last dose was received between 6 and 12 months before the signing of the ICF and the participant has a CD19+ count below the lower limit of normal.
Note: Participants who have received the last dose of anti-CD20 treatment >12 months before the signing of the ICF are not excluded from clinical trial participation based on this criterion and are not required to undergo CD19+ testing.
-
Within 4 months of the screening visit, use of either a) systemic corticosteroids at an average dose of 40 milligrams (mg) prednisone equivalent or higher for more than 14 days or b) oral budesonide delayed release capsules.
-
The participant has received a live or live-attenuated vaccine within 4 weeks before signing the ICF or has any live or live-attenuated vaccine planned during the clinical trial.
-
Participation in any other investigational drug trial (including vaccine trial) with receipt of at least 1 dose of investigational drug, or has been exposed to another investigational agent within 4 weeks or 5 half-lives, whichever is longer, before Visit 1.
-
The participant has active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
-
The participant has had any of the following types of infections within the specified timeframes where applicable:
- Active bacterial, viral, or fungal infection (except for the common cold and onychomycosis), or any other serious infection within 2 weeks of signing the ICF. Any anti-infective course for infection must be completed at least 2 weeks before Visit 1.
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) infection within 4 weeks of signing the ICF.
- Opportunistic infection or treatment for an opportunistic infection less than or equal to (≤)12 weeks before signing the ICF.
- Active tuberculosis (TB), any history of prior active TB, or any signs or symptoms of active TB infection (including but not limited to chronic fever, chronic productive cough, night sweats, weight loss, or malnutrition) as judged by the investigator.
- For participants in European Union (EU) member states, positive or 2 indeterminant QuantiFERON results, unless there is documentation of prior complete treatment for latent TB, or participant has initiated prophylaxis based on local guidelines and in consultation with a pulmonology or infectious disease specialist prior to the first administration of IMP.
-
In the opinion of the investigator, the participant is currently experiencing any medical condition that might interfere with participation in the trial (for example, significant ocular, cardiovascular, pulmonary, hematologic, gastrointestinal, endocrinologic, hepatic, renal, neurologic, malignancy, infectious disease, immunodeficiency, or alcohol and drug abuse), that poses an added risk for the participant or could confound the assessment of trial results.
-
In the opinion of the investigator, the participant has a serious medical or psychiatric illness that could potentially interfere with the completion of treatment.
-
The participant has a history of major surgery within 3 months before screening (or longer, at the discretion of the investigator); or, either has a planned tonsillectomy or underwent a tonsillectomy within 6 months before screening.
Note: Major surgery typically requires at least 1 night in the hospital.
-
History of malignancy (including myelodysplastic syndrome) within 5 years of signing the ICF, except for adequately treated non-melanoma skin cancer, superficial bladder cancer, and curatively treated cervical carcinoma-in-situ.
-
The participant has a history of a severe allergic or anaphylactic reaction to recombinant proteins or excipients used in the mezagitamab or placebo formulation.
-
The participant has (1) been diagnosed with or has suspected chronic obstructive pulmonary disease (COPD) or asthma and (2) has a prebronchodilatory forced expiratory volume in 1 second (FEV1) <50% of predicted normal at screening.
-
The participant is capable of breastfeeding but does not agree to forego breastfeeding from first dose of investigational medicinal product (IMP) through 30 days after the last dose of IMP.
-
The participant is an individual with potential for pregnancy but does not agree to use at least 1 form of highly effective contraception and 1 barrier method of contraception (preferably male condom) when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.
-
The participant is a sexually active, non-sterilized individual who produces sperm but does not agree to use a barrier method (preferably male condom) combined with at least 1 form of highly effective contraception for any partner(s) with potential for pregnancy when engaging in heterosexual sex for the protocol specified duration after the last dose of IMP.
-
In the investigator's opinion, the participant (and the participant's legally acceptable representative, if applicable per local regulations or determination) is unwilling and/or unable to understand and fully comply with clinical trial procedures and requirements (including digital tools and applications).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Mezagitamab
Participants will receive mezagitamab injections, subcutaneously (SC), for approximately 22 weeks. |
Mezagitamab injections administered SC.
다른 이름들:
|
|
위약 비교기: Placebo
Participants will receive mezagitamab-matching placebo injections, SC for approximately 22 weeks. |
Mezagitamab-matching placebo injections administered SC. |
|
실험적: Open-label Mezagitamab
Participants will receive mezagitamab injections, SC for approximately 22 weeks. |
Mezagitamab injections administered SC.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in Proteinuria at Week 36
기간: From Baseline to Week 36
|
Proteinuria will be assessed by urine protein to creatinine ratio (UPCR) calculated from a 24-hour urine collection. |
From Baseline to Week 36
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
각각 52 주와 104 주에 추정 된 사구체 여과율 (EGFR)의 기준선에서 변화
기간: 기준에서 52 주 및 104 주까지
|
기준에서 52 주 및 104 주까지
|
|
|
Time From Baseline to the First Occurrence of Sustained Decline in eGFR of ≥30 Percent (%) From Baseline Over at Least 4 Weeks
기간: From Baseline to Week 104
|
From Baseline to Week 104
|
|
|
Percentage of Participants Who Achieve ≥30% Reduction From Baseline in Proteinuria at Week 104
기간: From Baseline to Week 104
|
From Baseline to Week 104
|
|
|
The Rate of Change in eGFR From Baseline at Week 104
기간: From Baseline to Week 104
|
The rate of change in eGFR from baseline is measured as eGFR total slope. |
From Baseline to Week 104
|
|
Time from Baseline to the First Occurrence of Any of the Pre-specified Kidney Failure Composite Assessment Criteria
기간: From Baseline to Week 104
|
The pre-specified assessment criteria will include: sustained decline in eGFR of ≥30% from baseline over at least 4 weeks; sustained eGFR <15 mL/min/1.73 m^2 over at least 4 weeks; initiation of maintenance dialysis defined as dialysis performed for at least 4 weeks; receipt of kidney transplant; or death from kidney failure. Time from baseline to first occurrence of any of the above assessment criteria would be reported. |
From Baseline to Week 104
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Study Director, Takeda
간행물 및 유용한 링크
유용한 링크
- <p>Click here to ask Takeda's chatbot for comprehensive and easy-to-understand information about clinical trials - even across products and indications - in your local language.</p>
- <p>Click here for more information about this trial in easy-to-understand language, including a Plain Language Summary of the results if the trial has been completed.</p>
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- TAK-079-3001
- 2025-520825-19-00 (씨티스)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD 공유 액세스 기준
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .